Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PluroGel · 1 trial · 1 indication
Days to over 80% area of burn injury healed
| Arm | Type | Description |
|---|---|---|
| Standard dressing | ACTIVE_COMPARATOR | Topical antibiotic ointment (Polysporin™ or formulary equivalent) and non-adherent petrolatum fine-meshed gauze (ADAPTIC™) applied every Monday, Wednesday and Friday (or equivalent). |
| Test dressing | EXPERIMENTAL | A 0.5 cm layer of PluroGel® followed by the above standard dressing. In addition, this will be covered with moistened gauze, kept moist twice daily. (The additional factors are the use of PluroGel® and moistened gauze. Standard dressing will continue to be used.) |
| Name | Type | Description |
|---|---|---|
| PluroGel | DRUG | A 0.5 cm layer of PluroGel® followed by the above standard dressing. In addition, this will be covered with moistened gauze, kept moist twice daily. (The additional factors are the use of PluroGel® and moistened gauze. Standard dressing will continue to be used.) |
| Standard dressing | DRUG | Topical antibiotic ointment (Polysporin™ or formulary equivalent) and non-adherent petrolatum fine-meshed gauze (ADAPTIC™) applied every Monday, Wednesday and Friday (or equivalent). |
Inclusion Criteria: * Persons with partial thickness face burns or unilateral limb burn injuries requiring admission. Exclusion Criteria: * Total burn surface area (TBSA) \>30%. * Burn depth full thickness or deeper on initial assessment. * Prior excision at another healthcare centre. * Patients ...
PluroGel is an investigational small molecule being developed for the treatment of burns. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities. The drug is being studied as a topical dressing for burn injuries.
PluroGel is being developed by Medline Inc., a company traded under the ticker symbol MDLN. The company is conducting clinical research to evaluate the safety and efficacy of PluroGel for the treatment of burns.
PluroGel is currently in Phase 1 clinical development. It is an investigational drug and has not yet received regulatory approval. The ongoing Phase 1 trial is actively recruiting participants to study the drug's effects in patients with burn injuries.
PluroGel is being studied in a Phase 1 clinical trial with the identifier NCT05000983. This trial is titled 'A Between Patient Study of Plurogel® Compared to Standard Topical Dressing in Burn Injuries' and is currently recruiting participants in Canada.
Yes, PluroGel and Plurogel refer to the same investigational drug. The clinical trial NCT05000983 uses the spelling 'Plurogel' in its title, while the drug name is commonly written as 'PluroGel'. Both names refer to the same product being developed by Medline Inc.